FDA authorizes software that can help identify prostate cancer
Today, the U.S. Food and Drug Administration authorized marketing of software to assist medical professionals who examine body tissues (pathologists) in the detection of areas that are suspicious for cancer as an adjunct (supplement) to the review of digitally-scanned slide images from prostate biopsies (tissue removed from the body).
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
More News: Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Marketing | Pathology | PET Scan | Pharmaceuticals | Prostate Cancer